Research & Development at Novartis The Novartis Pharmaceuticals clinical pipeline holds a broad stream of 140 future projects including both new molecular entities and additional indications or formulations for marketed products. Our pipeline has consistently being ranked by experts as one of the strongest in the industry. Our scientists focus on diseases for which medical need remains unmet and strive to improve the drug discovery process with an approach that integrates novel concepts and tools across multiple disease areas.
ReSET-O(TM)* is the first US FDA-cleared prescription digital therapeutic for patients with Opioid Use Disorder Cleared by the FDA in December, reSET-O is available immediately As part of a broader focus on digital healthcare solutions at Novartis, Sandoz aims to increase patient engagement and improve access to treatment through digital solutions HOLZKIRCHEN, January 7, 2018 - Sandoz Inc.
Basel, December 21, 2018 - Novartis today announced that the European Commission (EC) approved an expanded indication for Kisqali (ribociclib), the CDK4/6 inhibitor with the largest body of first-line clinical trial evidence demonstrating consistent and sustained efficacy compared to endocrine therapy alone.
Susanne Schaffert, Ph.D., President, AAA, an established Novartis executive, named new CEO, Novartis Oncology Basel, December 20, 2018 - Novartis announced today that Susanne Schaffert, Ph.D., currently President, Advanced Accelerator Applications (AAA), a Novartis company, has been appointed CEO Novartis Oncology.
Agreement covers biosimilar insulins in early and clinical development for the top three selling branded insulins by sales: glargine, lispro and aspart Over 400 million people worldwide have diabetes and the amount of insulin required to treat type 2 diabetes alone is expected to increase by more
ReSET-O TM is the first FDA-cleared Prescription Digital Therapeutic (PDT) for patients with Opioid Use Disorder Pear Therapeutics is leading the development of a new therapeutic class with two FDA-authorized PDTs and a robust pipeline of therapeutics across disease areas Sandoz will lead U&perio
Adds 177 Lu-PSMA-617, a potential first-in-class radioligand therapy in Phase III development for metastatic castration-resistant prostate cancer (mCRPC) - Strengthens leadership in nuclear medicine and radioligand therapy for treating cancer - Complements the robust Advanced Accelerator Appl
Proposed acquisition builds on existing agreement with CellforCure for contract manufacturing of Novartis leading CAR-T cell therapy Kymriah (tisagenlecleucel) and recent successful completion of technology transfer - If completed, this acquisition would bolster CAR-T cell therapy manufacturing
Acquisition further expands Alcon's portfolio of comprehensive solutions for patients with dry eye Tear Film's iLux Device offers innovative, customizable treatment for Meibomian Gland Dysfunction, a leading cause of dry eye Alcon plans to further expand availability of this technology throughout the U.S. and Canada in early 2019.
The EC approval underscores the long-term safety and efficacy of Xolair demonstrated in clinical studies and by 13 years of real-world use in Europe - Xolair (omalizumab) prefilled syringe (PFS) is the first and only biologic to receive European Commission (EC) approval for self-administration
Subgroup analyses of three pivotal Phase III MONALEESA trials showed Kisqali plus endocrine therapy extended PFS in all patients with and without visceral involvement compared to endocrine therapy alone; consistent with the overall study populations In patients with visceral metastasis, incre
LinkMedicine and Life Sciences
Last job offers
- Continuing Education - 16.1
Young Investigator Group Preparation Program at Karlsruhe Institute of Technology (KIT) in Germany
- Music - 16.1
Dozent / Dozentin Musiktheorie (80-100%)
- Earth Sciences - 16.1
Marine Applications Expert (VN18 84)
- Microtechnics - 15.1
Research Team Leader for IoT in Building Systems
- Astronomy/Space Science - 14.1
Manager for the EPFL Space Center
- Computer Science/Telecom - 11.1
Scientific Programmer in Machine Learning (80-100%)
- Physics - 16.1
Postdoc: Nonlinear dynamic atomic force microscopy (3mE19-05)
- Veterinary Science - 16.1
Senior Lecturer in Diagnostic Imaging